SPRY logo

ARS Pharmaceuticals Inc. (SPRY)

$3.65

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on SPRY

Market cap

$366928660

EPS

-2.01

P/E ratio

--

Price to sales

3.6

Dividend yield

--

Beta

0.969468

Price on SPRY

Previous close

$3.59

Today's open

$3.51

Day's range

$3.51 - $3.79

52 week range

$2.44 - $13.15

Profile about SPRY

CEO

Donn Casale

Employees

163

Headquarters

San Diego, CA

Exchange

NASDAQ Global Market

Shares outstanding

100528400

Issue type

Common Stock

SPRY industries and sectors

Healthcare

Biotechnology & Life Sciences

News on SPRY

ARS Pharmaceuticals: Neffy Is Gaining Traction, But Revenue Growth Needs To Catch Up

ARS Pharmaceuticals remains a Hold into 1Q27; targeted commercial progress is encouraging, but stronger revenue growth and operating leverage need proof. Neffy demand rose 42%, but U.S. net product revenue grew just 7%; targeted-account share reached 9%, while gross-to-net remained around 50%. SPRY cut quarterly SG&A to $43.5 million and reaffirmed year-end 2027 cash flow breakeven, but liquidity fell to $138.4 million.

news source

Seeking Alpha • 11 hours ago

news preview

ARS Pharmaceuticals Analysts Cut Their Forecasts After Downbeat Q3 Results

ARS Pharmaceuticals (NASDAQ:SPRY) on Thursday reported weaker-than-expected results for the third quarter.

news source

Benzinga • Nov 6, 2026

news preview

ARS Pharmaceuticals, Inc. (SPRY) Q3 2026 Earnings Call Transcript

ARS Pharmaceuticals, Inc. ( SPRY ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Donn Casale - CEO, President & Director Meg Smith Kathleen Scott - Chief Financial Officer Conference Call Participants Monique Allaire - Thrust Strategic Communications Joshua Schimmer - Cantor Fitzgerald & Co., Research Division Frank Wang Zhong - Leerink Partners LLC, Research Division Lachlan Hanbury-Brown - William Blair & Company L.L.C., Research Division Presentation Operator Good afternoon, and welcome to ARS Pharma's Third Quarter 2026 Earnings Conference Call.

news source

Seeking Alpha • Nov 6, 2026

news preview

ARS Pharmaceuticals Q3 Earnings Call Highlights

ARS Pharmaceuticals NASDAQ: SPRY reported $33.4 million in third-quarter U.S. net product revenue from its needle-free epinephrine treatment neffy and reaffirmed its goal of reaching cash flow breakeven by the end of 2027.

news source

MarketBeat • Nov 6, 2026

news preview

ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Lags Revenue Estimates

ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to a loss of $0.52 per share a year ago.

news source

Zacks Investment Research • Nov 5, 2026

news preview

ARS Pharmaceuticals: Lawsuits And Cash Burn Are Priced In, Yet The Stock Keeps Falling

ARS Pharmaceuticals is rated Buy, with current market pricing disconnected from fundamental pipeline value despite commercial setbacks. neffy, the flagship intranasal epinephrine spray, faces slow adoption and insurance hurdles but shows potential for significant market share and revenue. Management pivots to a leaner, targeted prescriber approach, aiming for late-2027 cash-flow breakeven while addressing heavy cash burn and term debt.

news source

Seeking Alpha • Nov 3, 2026

news preview

ARS Pharmaceuticals, Inc. (SPRY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

ARS Pharmaceuticals, Inc. (SPRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

news source

Zacks Investment Research • Oct 29, 2026

news preview

ARS Pharma to Report Third Quarter 2026 Financial Results

SAN DIEGO, Oct. 28, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions, today announced the company will host a conference call and webcast on Thursday, November 5, 2026, at 1:30 p.m. PT / 4:30 p.m. ET to review its third quarter 2026 financial results.

news source

GlobeNewsWire • Oct 28, 2026

news preview

SPRY FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

NEW YORK--(BUSINESS WIRE)---- $SPRY #ARS--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against ARS Pharmaceuticals Inc. ("“ARS Pharmaceuticals” or the “Company”) (NASDAQ: SPRY) and reminds investors of the October 5, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California an.

news source

Business Wire • Oct 5, 2026

news preview

SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law

LOS ANGELES--(BUSINESS WIRE)---- $SPRY--SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law.

news source

Business Wire • Oct 5, 2026

news preview

¹ Disclosures

Get started with M1

Invest in ARS Pharmaceuticals Inc.

Open an M1 investment account to buy and sell ARS Pharmaceuticals Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in SPRY on M1